Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure

• US 9,526,747 B2
• Filed: 11/21/2011
• Issued: 12/27/2016
• Est. Priority Date: 08/05/1999
• Status: Expired due to Term

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Verfaillie, Catherine M., Reyes, Morayma, Furcht, Leo T.
• Primary Examiner(s): BERKE-SCHLESSEL, DAVID W
• Application Number:
  US13/301,186
• Publication Number:
  US 20120064047A1
• Time in Patent Office: 1,863 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2500/36 Lipids
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2501/105 Insulin-like growth factors [IGF]
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2501/33 Insulin together with transferrin C12N2500/25; Insulin-like growth factors C12N2501/105
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2533/52 Fibronectin; Laminin
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells in cardiac indications.

Claims

1. A method of providing cardiac muscle to a subject in need thereof, said method comprising administering to the subject, in an amount effective to provide new cardiac muscle, isolated expanded human multipotent non-ES, non-germ cells that express telomerase, have the capacity to undergo 40 cell doublings in culture and have a normal karyotype, wherein the existing cardiac muscle is damaged by disease or injury.

2. The method of claim 1 wherein the non-embryonic, non-germ cells further express one or more of oct4, rex-1, rox-1, or sox-2.

3. The method of either of claims 1 or 2, wherein the disease is selected from the group consisting of congestive heart failure, coronary artery disease, myocardial infarction, myocardial ischemia, atherosclerosis, cardiomyopathy, idiopathic cardiomyopathy, cardiac arrhythmias, muscular dystrophy, muscle mass abnormality, muscle degeneration, infective myocarditis, drug- or toxin-induced muscle abnormalities, hypersensitivity myocarditis, autoimmune endocarditis, and congenital heart disease.

4. The method of claim 1 wherein the cells are derived from bone marrow.

5. The method of claim 1 wherein the cells have undergone 10-40 cell doublings in culture.

6. The method of claim 1 wherein the cells can differentiate into at least one cell type of at least two of the endodermal, ectodermal and mesodermal embryonic lineages.

7. The method of claim 6 wherein the cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.